Loading...
•
Dec 31, 2022
Intra-Cellular Q4 2022 Earnings Report
Intra-Cellular Therapies reported Q4 2022 financial results, highlighting significant growth in CAPLYTA sales and advancements in clinical programs.
Key Takeaways
Intra-Cellular Therapies reported a net loss of $44.0 million for Q4 2022, with CAPLYTA net product sales reaching $87.4 million, a 243% increase year-over-year. The company's full-year revenue for 2022 was $250.3 million, driven by CAPLYTA's strong performance.
CAPLYTA net product sales for Q4 2022 reached $87.4 million, a 243% increase compared to Q4 2021.
The company's net loss for Q4 2022 was $44.0 million, an improvement from the $85.7 million loss in Q4 2021.
Full year 2022 total revenues were $250.3 million, compared to $83.8 million in 2021.
CAPLYTA prescriptions tripled in 2022, with a 225% increase in Q4 2022 compared to Q4 2021.
Intra-Cellular
Intra-Cellular
Forward Guidance
Intra-Cellular Therapies anticipates continued growth for CAPLYTA in 2023, with net product sales expected to be in the range of $430 to $455 million.
Positive Outlook
- CAPLYTA 2023 net product sales are expected to be $430 to $455 million.
- SG&A guidance reflects our commitment to continue to support CAPLYTA commercialization through investments in our sales and marketing activities.
- R&D guidance reflects investments to support our robust pipeline including our lumateperone clinical programs in mood disorders, our long-acting injectable program, and our other platforms including our phosphodiesterase-1 inhibitors, ITI-1284 and ITI-333.
- Expect to file a supplemental New Drug Application with the FDA for approval of lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD in 2024.
- Expect to report topline results from Study 403 in the first quarter of 2023.